Upstream Bio
UPB | NASDAQ
$2.15
-$0.63 (-22.66%)
At close: Nov 16, 2026, 4:00 PM ET
$2.19
+$0.04 (+1.64%)
After-hours:
Nov 16, 2026, 7:36 PM ET
-22.66%
(1D)No price chart data available for 1D timeframe.
Rating
42.2
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #468/1021 (Top 46%)
Key Statistics
Market Data
Market Cap $117.84M
1D Range
2.12 2.83
52W Range
2.12 32.60
Valuation (TTM)
PE -0.71
PB 0.50
EV/EBITDA 0.54
Valuation (NTM)
Forward PE N/A
Forward PEG -0.09
Price Target $25.00
Cash Flow
FCF Yield -142.9%
SBC Adj. FCF Yield -156.3%
SBC Impact -9.4%
Margins
Gross Margin 98.3%
Operating Margin -6116.0%
FCF Margin -5867.2%
Growth (CAGR)
Revenue 3Y | 5Y 66.6% |
N/A
Dil EPS 3Y | 5Y -34.3% |
N/A
FCF 3Y | 5Y -48.6% |
N/A
Returns
ROA -66.7%
ROE -57.1%
ROIC -74.8%
Financial Health
Net Cash
$207.37M
Current Ratio 20.45
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory syst...
Sector Healthcare
Industry Biotechnology
Employees 75
IPO Date Oct 11, 2024
Website upstreambio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 10, 2026
EPS
-$0.75
Miss -2.55%
YoY:
-19.05% REV
$395K
Miss -28.02%
YoY:
-42.17%Next Earnings
Mar 17, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
5
Consensus
Buy
Price Target
$25.00
Upside
+1062.79%
Buy (3)
Hold (2)
Sell (0)
Add to Watchlist
Select watchlists to add or remove UPB